Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06723457 · ClinicalTrials.gov registry record · Phase 2

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

A Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma, sponsored by Northwestern University.

Active
Registry status
Phase 2
Development phase
34
Enrollment target
1
Study location

NCT06723457: Active Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma, sponsored by Northwestern University.

NCT06723457 is a Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 34 participants, below the 46-participant average among 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06723457, a Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come back after a period of improvement (relapsed). Epcoritamab is an immunotherapy that engages T-cells in the immune system to help redirect their killing effects against lymphoma cells. Lenalidomide can modulate the immune system to enhance killing effects of lymphoma by the immune system as well. Giving patients a combination of epcoritamab and lenalidomide may work better in treating refractory or relapsed immunodeficiency-related large B-cell lymphoma.

Primary Outcome

The combination of epcoritamab-lenalidomide in chemotherapy ineligible patients with primary refractory or relapsed immunodeficiency-related large B-cell lymphoma, indicated by the number of patients with CR as best response (using the Lugano Criteria) divided by the total number of patients who have received 1 dose of combination therapy and have had response assessment by radiographic imaging by 6 months from start of therapy. The six-month best response of CR rate will be estimated by the num

Conditions Studied

Refractory B-Cell Non-Hodgkin Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • DRUG Lenalidomide
  • BIOLOGICAL Epcoritamab

Study Locations (1)

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2025-07-25
Est. Completion 2029-02-18
Phase Phase 2
Northwestern University

1,209 total trials

What the registry record for NCT06723457 still lists

NCT06723457 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 46-participant average among 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (26% lower).

The record links to 3 conditions, with Refractory B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06723457 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06723457 about?

NCT06723457 is a clinical study titled "Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma". This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come back after a period of improvement (relapsed). Epcoritamab is an immunothe...

What is the current status of trial NCT06723457?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2025-07-25. Estimated completion is 2029-02-18.

What conditions does trial NCT06723457 study?

This clinical trial studies the following conditions: Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder.

What interventions are being tested in trial NCT06723457?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Lenalidomide (DRUG), Epcoritamab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06723457?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06723457 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory B-Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06723457's enrollment target sits among peer trials

34 8th of 15 higher than 8 of 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Refractory B-Cell Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06723457, the US trial registry maintained by the National Library of Medicine. NCT06723457 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.